Clinical Commissioning Policy: Stereotactic ablative radiotherapy (SABR) for patients with metachronous extracranial oligometastatic cancer (all ages)

SABR will be available as treatment option via routine commissioning for patients with controlled primary cancer presenting with upto 3 extracranial metachronous oligometastases which occur after disease-free interval following primary treatment, in line with specified criteria.


NHS England